Classifications

• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/17—Amino acids, peptides or proteins
  • A23L33/175—Amino acids
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23K—FODDER
  • A23K20/00—Accessory food factors for animal feeding-stuffs
  • A23K20/10—Organic substances
  • A23K20/142—Amino acids; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23K—FODDER
  • A23K20/00—Accessory food factors for animal feeding-stuffs
  • A23K20/10—Organic substances
  • A23K20/158—Fatty acids; Fats; Products containing oils or fats
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
  • A23L33/12—Fatty acids or derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
  • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4164—1,3-Diazoles
  • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P39/00—General protective or antinoxious agents
  • A61P39/06—Free radical scavengers or antioxidants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the present invention relates to oral compositions containing ergothioneine or a salt thereof and at least one eicosapentaenoic acid.
• the present invention also relates to the use of at least one eicosapentaenoic acid for suppressing the bitterness derived from ergothioneine or its salt.
• the present invention relates to a method for suppressing bitterness derived from ergothioneine or a salt thereof and odor derived from eicosapentaenoic acids.
• Ergothioneine is one of the hydrophilic sulfur-containing amino acids and is known to have various physiological activities including antioxidant ability.
• Patent Document 1 reports immune response activation cytokine production promotion action and the like.
• ergothioneine has attracted attention as a food, cosmetic, and pharmaceutical product because of its various physiological activities.
• EPA eicosapentaenoic acid
• Patent Document 2 discloses a pharmaceutical composition containing EPA and nicotinic acid.
• ergothioneine since ergothioneine has useful physiological activities, foods such as supplements containing ergothioneine or salts thereof are useful for maintaining or promoting health.
• ergothioneine or a salt thereof has a unique flavor, particularly an unpleasant bitterness that stings the tongue (bitterness), and there is room for improvement in making it an oral composition.
• Foods such as supplements containing EPA are similarly useful, but there is a problem that EPA and its derivatives have an unpleasant flavor (smell). . Therefore, an oral composition containing ergothioneine or a salt thereof and an eicosapentaenoic acid can be expected to have various useful effects, but is thought to have problems of bitterness and odor.
• An object of the present invention is to provide an oral composition containing ergothioneine or a salt thereof and at least one eicosapentaenoic acid, in which the bitterness derived from ergothioneine or a salt thereof and the odor derived from eicosapentaenoic acids are reduced.
• Another object of the present invention is to provide use of at least one kind of eicosapentaenoic acid for suppressing the bitterness derived from ergothioneine or a salt thereof.
• the present invention provides a method for suppressing the bitterness derived from ergothioneine or a salt thereof and the odor derived from eicosapentaenoic acids in an oral composition containing ergothioneine or a salt thereof and at least one eicosapentaenoic acid.
• the present inventors found that when ergothioneine or a salt thereof and at least one eicosapentaenoic acid are combined in a specific weight ratio, bitterness derived from ergothioneine or a salt thereof and bitterness derived from eicosapentaenoic acids It has been found that the odor of can be effectively suppressed.
• the present invention includes the following oral compositions and the like.
• composition according to [1] above, wherein the eicosapentaenoic acids are selected from the group consisting of free eicosapentaenoic acid, salts thereof, and compounds containing eicosapentaenoic acid as a constituent fatty acid.
• the compound containing eicosapentaenoic acid as a constituent fatty acid is a triglyceride in which part or all of the constituent fatty acid is eicosapentaenoic acid, a diglyceride in which part or all of the constituent fatty acid is eicosapentaenoic acid, and the constituent fatty acid is eicosapentaene.
• composition according to any one of [5] The composition according to any one of [1] to [4] above, wherein component (B) is derived from seafood.
• component (B) is derived from seafood.
• component (B) eicosapentaene A method for suppressing the bitterness derived from ergothioneine or a salt thereof and the odor derived from eicosapentaenoic acids, wherein the weight ratio ((B)/(A)) of acid conversion) is adjusted to 0.5 to 15.
• an oral composition containing ergothioneine or a salt thereof and at least one eicosapentaenoic acid in which the bitterness derived from ergothioneine or a salt thereof and the odor derived from eicosapentaenoic acids are reduced.
• use of at least one kind of eicosapentaenoic acid for suppressing bitterness derived from ergothioneine or a salt thereof can be provided.
• a method for suppressing bitterness derived from ergothioneine or a salt thereof and odor derived from eicosapentaenoic acids in an oral composition containing ergothioneine or a salt thereof and at least one eicosapentaenoic acid be able to.
• the oral composition of the present invention (hereinafter also referred to as “the composition of the present invention") comprises the following components (A) and (B): (A) ergothioneine or a salt thereof, and (B) at least one
• the weight ratio ((B)/(A)) of component (B) (eicosapentaenoic acid equivalent) to component (A) (ergothioneine equivalent) is 0.5-15.
• Ergothioneine is a kind of sulfur-containing amino acid.
• ergothioneine is preferably L-ergothioneine.
• the salt of ergothioneine is not particularly limited as long as it is a pharmacologically acceptable salt or a salt acceptable for food and drink, and may be either an acid salt or a basic salt.
• Acid salts include, for example, inorganic salts such as hydrochlorides, sulfates, nitrates, phosphates; Examples include organic acid salts such as acid salts and propionate salts.
• Examples of basic salts include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts;
• Ergothioneine or a salt thereof is not at all limited by its form, production method, and the like. Ergothioneine or a salt thereof may be a chemically synthesized product, or may be extracted and purified from natural products. A large amount of L-ergothioneine is contained in Golden/Yellow Oyster Mushroom (scientific name: Pleurotus cornucopiae var. citrinopileatus), which is a mushroom belonging to the genus Pleurotus of the Oysteraceae family.
• Golden/Yellow Oyster Mushroom scientific name: Pleurotus cornucopiae var. citrinopileatus
• L-ergothioneine is found in white button mushrooms, crimini mushrooms, portabella mushrooms and other mushrooms (scientific name: Agaricus bisporus), gray oyster mushrooms (scientific name: Pleurotus ostreatus), shiitake mushrooms (scientific name: Lentinula edodes), maitake mushrooms (Scientific name: Grifola frondosa), Reishi (Scientific name: Ganoderma lucidum), Hericium erinaceus (Scientific name: Hericium erinaceus), Willow matsutake (Scientific name: Agrocybeaegerita), Chanterelle (Scientific name: Cantharellus cibarius), Porcini Name: Boletus edulis), morels ( It is also contained in mushrooms such as Morchella esculenta (scientific name: Morchella esculenta).
• L-ergothioneine When L-ergothioneine is obtained from a natural product, it is preferably extracted from Pleurotus cornucopia. Ergothioneine or a salt thereof can also be produced by microbial fermentation. Ergothioneine or a salt thereof may be isolated.
• composition of the present invention contains ergothioneine or a salt thereof and at least one eicosapentaenoic acid in the above ratio, thereby reducing the bitterness derived from ergothioneine or a salt thereof and the odor derived from the eicosapentaenoic acid. be. This facilitates continuous intake of ergothioneine or a salt thereof and eicosapentaenoic acids.
• eicosapentaenoic acids eicosapentaenoic acid (free eicosapentaenoic acid), salts thereof and derivatives thereof can be used.
• Eicosapentaenoic acids may be used singly or in combination of two or more.
• derivatives of eicosapentaenoic acid for example, a compound having a structure in which eicosapentaenoic acid is bound and a compound capable of separating eicosapentaenoic acid by hydrolysis can be used.
• Compounds that can separate eicosapentaenoic acid by hydrolysis include compounds containing eicosapentaenoic acid as a constituent fatty acid.
• the eicosapentaenoic acids used in the present invention are preferably selected from the group consisting of free eicosapentaenoic acid, salts thereof, and compounds containing eicosapentaenoic acid as a constituent fatty acid.
• Salts of eicosapentaenoic acid include, for example, calcium salts and sodium salts.
• Compounds containing eicosapentaenoic acid as a constituent fatty acid include triglycerides in which part or all of the constituent fatty acid is eicosapentaenoic acid, diglycerides in which part or all of the constituent fatty acid is eicosapentaenoic acid, and eicosapentaenoic acid as the constituent fatty acid.
• a compound selected from the group consisting of monoglycerides, phospholipids in which part or all of the constituent fatty acid is eicosapentaenoic acid, glycolipids in which part or all of the constituent fatty acid is eicosapentaenoic acid, and alcohol esters of eicosapentaenoic acid. is preferred.
• the eicosapentaenoic acids are more preferably triglycerides, diglycerides and phospholipids in which part or all of the constituent fatty acid is eicosapentaenoic acid, and more preferably triglycerides and diglycerides in which part or all of the constituent fatty acid is eicosapentaenoic acid.
• Particularly preferred are triglycerides in which part or all of the constituent fatty acids are eicosapentaenoic acid.
• the eicosapentaenoic acids used in the present invention are not limited in any way by their forms, production methods, etc. Chemically synthesized products may be used, and those derived from natural products and genetically modified organisms (Escherichia coli, yeast, Plants, etc.) may also be used. Examples of those derived from natural products include those derived from fish and shellfish, algae, fungi (labyrinthula, etc.), and plants (marcella, etc.) that have the ability to produce EPA. Among them, eicosapentaenoic acids are preferably derived from fish and shellfish.
• eicosapentaenoic acids extracted and/or purified from raw materials such as natural products containing eicosapentaenoic acids may be used, or the raw materials may be used as they are and the eicosapentaenoic acids may be contained in the composition.
• Raw materials containing eicosapentaenoic acids include, for example, edible oils and fats such as oils and fats extracted from fish oils, eggs, meats, milks and algae.
• the fish oil containing eicosapentaenoic acids is preferably a fish oil concentrated so that the content of eicosapentaenoic acids (eicosapentaenoic acid equivalent) is 5% by weight or more, preferably 10% by weight or more, more preferably 20% by weight or more.
• eicosapentaenoic acids extracted and/or purified from fish oil containing eicosapentaenoic acids may be used, or the fish oil may be used as it is.
• the oral composition of the invention contains fish oil, and the eicosapentaenoic acids may be part of the fish oil.
• the weight ratio ((B)/(A)) of component (B) (eicosapentaenoic acid equivalent) to component (A) (ergothioneine equivalent) is 0.5-15.
• the weight ratio is preferably 1-15, more preferably 2-14.
• the amount in terms of ergothioneine or a similar expression means the amount when the component (A) is ergothioneine, and when the component (A) is a salt of ergothioneine, the number of moles of the salt, It means the value obtained by multiplying the molecular weight of ergothioneine.
• the amount in terms of eicosapentaenoic acid or a similar expression means the amount when the component (B) is free EPA, and when the component (B) is not free EPA, saponification treatment or enzyme It means the amount converted to free EPA by liberating EPA by treatment. When two or more kinds of eicosapentaenoic acids are contained, it is the total of these.
• the content of ergothioneine or a salt thereof contained in the composition of the present invention is not particularly limited, and can be set according to its form and the like.
• the content of ergothioneine or a salt thereof in the composition of the present invention is preferably 0.1% by weight or more, more preferably 0.5% by weight or more, and 1% by weight or more in terms of ergothioneine in the composition. is more preferably 1.5% by weight or more, preferably 50% by weight or less, more preferably 30% by weight or less, even more preferably 20% by weight or less, and particularly preferably 10% by weight or less.
• the content of ergothioneine or a salt thereof is preferably 0.1 to 50% by weight, more preferably 0.5 to 30% by weight, and 1 to 20% by weight in terms of ergothioneine in the composition of the present invention. is more preferred, and 1.5 to 10% by weight is particularly preferred.
• the content of ergothioneine can be measured by a high performance liquid chromatography (HPLC) method.
• the content of the eicosapentaenoic acids contained in the composition of the present invention is not particularly limited, and can be set according to its form and the like. When two or more kinds of eicosapentaenoic acids are contained, the above content is the total content thereof.
• the content of eicosapentaenoic acid can be measured by a gas chromatography (GC) method.
• the content of ergothioneine or a salt thereof is preferably 1 to 100 mg, more preferably 2 to 50 mg, more preferably 5 to 25 mg in terms of ergothioneine per day for adults. more preferably 5 to 20 mg, particularly preferably 5 to 20 mg.
• the content of eicosapentaenoic acids in the composition of the present invention is preferably 10 to 2500 mg, more preferably 25 to 1000 mg, more preferably 50 to 500 mg in terms of eicosapentaenoic acid per day for adults. is more preferable.
• Ergothioneine or its salts and eicosapentaenoic acids are compounds that are contained in natural products and foods and drinks and have been eaten. Therefore, from the viewpoint of safety, ergothioneine or its salts and eicosapentaenoic acids, for example, are considered to be ingested every day without any problem. According to the present invention, it is possible to provide a composition that is highly safe, has reduced bitterness derived from ergothioneine or a salt thereof and has reduced odor derived from eicosapentaenoic acids, and is easy to ingest.
• ergothioneine or a salt thereof is known to exhibit various physiological activities and health functions.
• UV absorption effect, melanin production inhibitory effect, reactive oxygen species scavenging effect, elastase activity inhibitory effect, wrinkle formation inhibitory effect, skin sagging inhibitory effect, autophagy promoting effect, etc. are known. Therefore, the composition of the present invention is used for antioxidant, brain function improvement, anti-aging, eye disease, whitening, ultraviolet absorption, suppression of melanin production, elimination of reactive oxygen species, and inhibition of elastase activity. , for suppressing wrinkle formation, for suppressing skin sagging, for promoting autophagy, and the like.
• Eicosapentaenoic acids are known to exert various health functions such as anti-inflammatory effect, blood triglyceride-reducing effect and anti-allergic effect. Since the composition of the present invention contains eicosapentaenoic acids, it can also be used to obtain the above-mentioned effects exhibited by eicosapentaenoic acids.
• compositions of the present invention can be applied for either therapeutic use (medical use) or non-therapeutic use (non-medical use).
• Non-therapeutic is a concept that does not involve medical intervention, i.e. human surgery, treatment or diagnosis.
• the composition of the present invention can be in the form of foods and beverages, pharmaceuticals, quasi-drugs, feeds, and the like.
• the composition of the present invention may be a material or formulation that is used by being blended in foods and beverages, pharmaceuticals, quasi-drugs, feeds, and the like.
• the composition of the present invention is an oral composition, and specific examples of the oral composition include food and drink, oral pharmaceuticals, quasi-drugs, feeds, etc., preferably food and drink or oral It is a pharmaceutical, more preferably a food or drink.
• composition of the present invention can contain optional additives and optional components as long as the effects of the present invention are not impaired.
• additives and ingredients can be selected according to the form of the composition, etc., and those generally usable for oral compositions such as food and drink, pharmaceuticals, quasi-drugs, and feeds can be used.
• a fat containing a fatty acid other than eicosapentaenoic acid or a fat containing no eicosapentaenoic acid can be added.
• the weight ratio of EPA in the total fatty acids constituting the fats and oils is preferably 5% by weight or more, more preferably 10% by weight or more, and still more preferably 15% by weight or more, Particularly preferably, it is 20% by weight or more.
• the n-3 ( ⁇ 3) fatty acid has the highest weight ratio of EPA.
• the method for producing the composition of the present invention is not particularly limited. It can be produced by blending. (A) ergothioneine or a salt thereof, and (B) in the preparation of an oral composition containing at least one eicosapentaenoic acid, component (B) (eicosapentaenoic acid equivalent) relative to component (A) (ergothioneine equivalent) By adjusting the weight ratio ((B)/(A)) to 0.5 to 15, it is possible to obtain an oral composition in which the bitterness derived from ergothioneine or a salt thereof and the odor derived from eicosapentaenoic acids are suppressed. can.
• Adjustment of the weight ratio can be performed by adding component (A) and/or component (B), for example.
• component (B) eicosapentaenoic acid equivalent
• component (B) eicosapentaenoic acid equivalent
• component (B) in terms of eicosapentaenoic acid
• fish oil containing the eicosapentaenoic acids described above may be incorporated in the preparation of oral compositions. Part or all of the eicosapentaenoic acids may be incorporated into the composition as part of the fish oil.
• the manufacturing method is not particularly limited, and it can be manufactured by a general method.
• the composition of the present invention may consist of ergothioneine or a salt thereof and eicosapentaenoic acids.
• the form of the oral composition of the present invention is not particularly limited, and may be solid (powder, granule, tablet, etc.), liquid, paste, or the like.
• composition of the present invention when used as a food or drink, ergothioneine or a salt thereof and eicosapentaenoic acids are blended with ingredients that can be used for food or drink (e.g., food materials, food additives used as necessary). It can be used as various foods and drinks.
• Food and drink are not particularly limited, and examples thereof include general food and drink, health food, health supplement, health drink, food with function claims, food for specified health use, and food and drink for sick people.
• Health foods, health supplements, foods with function claims, foods for specified health use, etc. are, for example, fine granules, tablets, granules, powders, capsules, chewables, dry syrups, syrups, liquids, beverages, and drinks. It can be used as various formulation forms such as medicines and liquid foods.
• composition of the present invention When the composition of the present invention is used as a drug or quasi-drug, for example, ergothioneine or a salt thereof and eicosapentaenoic acids are blended with a pharmacologically acceptable carrier, additives added as necessary, and the like. It can be used as pharmaceuticals or quasi-drugs in various dosage forms. Such carriers, additives, etc. may be those that can be used for pharmaceuticals or quasi-drugs and are pharmacologically acceptable. One or more of antioxidants, coloring agents and the like can be mentioned. Dosage forms for oral administration of pharmaceuticals or quasi-drugs include liquids, tablets, powders, fine granules, granules, sugar-coated tablets, capsules, suspensions, emulsions, chewables and the like.
• feed When the composition of the present invention is used as a feed, ergothioneine or a salt thereof and eicosapentaenoic acids may be added to the feed.
• Feed also includes feed additives. Examples of feeds include livestock feeds for cows, pigs, chickens, sheep, horses, etc.; small animal feeds for rabbits, rats, mice, etc.; pet foods for dogs, cats, small birds, etc.;
• Subjects to whom the composition of the present invention is ingested or administered are not particularly limited. Humans or non-human mammals are preferred, and humans are more preferred.
• the present invention also includes the following methods.
• component (B) eicosapentaenoic acid equivalent
• component (A) (ergothioneine equivalent) relative to component (A) (ergothioneine equivalent)
• bitterness derived from ergothioneine or a salt thereof and unpleasant flavor (smell) derived from eicosapentaenoic acids can be effectively suppressed.
• the present invention also includes the following uses.
• the weight ratio of at least one eicosapentaenoic acid (eicosapentaenoic acid conversion) to ergothioneine or a salt thereof (ergothioneine conversion) is preferably 0.5-15.
• ergothioneine or salts thereof and eicosapentaenoic acids and preferred embodiments thereof are the same as the compositions of the present invention described above.
• the preferred range of the weight ratio and amount of component (B) (eicosapentaenoic acid equivalent) to component (A) (ergothioneine equivalent) is also determined by component (A) in the composition of the present invention. ) (converted to ergothioneine) and the weight ratio of component (B) (converted to eicosapentaenoic acid) and the preferred range of the amount used.
• bitterness derived from ergothioneine or a salt thereof and the odor derived from EPA can be suppressed by the above methods and uses, they may be combined with other bitterness suppression methods and/or odor suppression methods.
• Other methods for suppressing bitterness include, for example, a method of adding a sweetening agent or a corrigent to a bitter component to prepare a formulation, a method of coating a bitter component with sugar coating to form a formulation, or encapsulating the bitter component into a capsule.
• a method of formulation and the like can be mentioned.
• Other odor-suppressing methods include, for example, a method of coating an odorous component with sugar coating to form a formulation, and a method of enclosing in a capsule to form a formulation.
• a range represented by “1-2” means from 1 to 2 and includes 1 and 2.
• the upper limit and the lower limit may be any combination of ranges.
• Ergothioneine Raw material containing 100% L-ergothioneine
• Eicosapentaenoic acids-containing oil Contains 20% by weight of eicosapentaenoic acids in terms of eicosapentaenoic acid, and among the constituent fatty acids, the weight ratio of EPA for n-3 fatty acids fat with the highest
• Examples 1-3 and Comparative Examples 1-2 Flavor evaluation test for oral compositions containing ergothioneine and eicosapentaenoic acids> An oral composition containing ergothioneine and eicosapentaenoic acids was prepared, and sensory evaluation was performed by three panelists skilled in sensory evaluation. Oral compositions of Examples 1 to 3 and Comparative Examples 1 and 2 were prepared using the above (A) and eicosapentaenoic acid-containing fats and oils in the amounts shown in Table 1.
• Each panelist placed the total amount of the prepared oral composition (e.g., 20 mg in Comparative Example 1) directly on the tongue, and measured the intensity of bitterness derived from ergothioneine and the intensity of odor derived from eicosapentaenoic acids according to the following criteria. evaluated.
• Evaluation criteria for bitterness derived from ergothioneine Evaluation was made on a scale of 1 to 5 (5 grades) according to the following criteria. As a reference point, the strength of the bitterness derived from ergothioneine felt when material (A) (10 mg) was placed on the tongue was rated as 5 points. Table 1 shows the average values (scores) of the evaluations of the three panelists. When the average value of the evaluation results was 4 points or less, it was evaluated that the bitterness was suppressed.
• Evaluation was made on a scale of 1 to 5 (5 grades) according to the following criteria.
• the strength of the odor derived from eicosapentaenoic acids felt when the eicosapentaenoic acid-containing oil (10 mg) was placed on the tongue was rated as 5 points.
• Table 1 shows the average values (scores) of the evaluations of the three panelists. When the average value of the evaluation results was 4 points or less, it was evaluated that the odor was suppressed.

Landscapes

• Life Sciences & Earth Sciences (AREA)
• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Polymers & Plastics (AREA)
• Engineering & Computer Science (AREA)
• Food Science & Technology (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Zoology (AREA)
• Nutrition Science (AREA)
• Epidemiology (AREA)
• Organic Chemistry (AREA)
• Mycology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Animal Husbandry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biochemistry (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Toxicology (AREA)
• Marine Sciences & Fisheries (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Cosmetics (AREA)
• Medicinal Preparation (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (1)

Family

ID=86902472

Family Applications (1)

Country Status (6)

Citations (4)

Family Cites Families (4)

• 2022
  • 2022-12-15 KR KR1020247022429A patent/KR20240127368A/ko active Pending
  • 2022-12-15 JP JP2023569372A patent/JPWO2023120368A1/ja active Pending
  • 2022-12-15 WO PCT/JP2022/046213 patent/WO2023120368A1/ja not_active Ceased
  • 2022-12-15 AU AU2022420207A patent/AU2022420207A1/en active Pending
  • 2022-12-15 CN CN202280084290.5A patent/CN118414093A/zh active Pending
  • 2022-12-22 TW TW111149416A patent/TW202342005A/zh unknown

Patent Citations (4)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events